A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Primary endpoints were changes in brachial artery flow-mediated vasodilation (FMD), carotid-femoral pulse wave velocity (PWV), and aortic augmentation index (AIx).

The 114 subjects were mean (standard deviation) 63.9 (3.0) years old with a 25-hydroxyvitamin D level of 31.3 (10.6) ng/mL.

Who Took Part

The study group was 114 subjects.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some subjects received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

Primary endpoints were changes in brachial artery flow-mediated vasodilation (FMD), carotid-femoral pulse wave velocity (PWV), and aortic augmentation index (AIx).

The 114 subjects were mean (standard deviation) 63.9 (3.0) years old with a 25-hydroxyvitamin D level of 31.3 (10.6) ng/mL.

The subject headings attached to it are Blood Glucose, Blood Pressure, Body Mass Index, Brachial Artery, Cardiovascular Diseases, Dietary Supplements and Heart Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 114 subjects.

The publication is from 2012 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.